---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-065308"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:48:13.923986+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "low"
source: SEC EDGAR
---

# Palvella announces Phase 3 SELVA topline results for QTORIN in lymphatic malformations; specifics not in filing excerpt

## Summary
- Topline data from Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations announced on Feb 24, 2026.
- Investor conference call held at 8:00 a.m. ET; presentation slides furnished as Exhibit 99.1.
- Exact efficacy and safety endpoints not disclosed in this filing excerpt; full results expected in the presentation.

## SEC filing metadata
- accession: 0001193125-26-065308
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/0001193125-26-065308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/pvla-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-065308
- JSON: https://secwatch.observer/filing/0001193125-26-065308.json
- Plain text: https://secwatch.observer/filing/0001193125-26-065308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.